Tuesday, August 18

Browsing: CD20

Research

Transport of cytotoxic cyanine dyes coupled to siRNA into hematopoietic cancer cells with CD20-, CD22- or CD33-targeting ELART nanocarriers

By NewsCancerAugust 18, 20260

Ali Zaidi, S. S. et al. Engineering siRNA therapeutics: challenges and strategies. J. Nanobiotechnol. 21, 381. https://doi.org/10.1186/s12951-023-02147-z (2023).Article Google Scholar …

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Flight Attendants and Pilots Have Highest Risk of Dying From Radiation-Linked Cancers, Study Says

New St. Jude CEO Dr. Charles Roberts Says Childhood Cancer Treatments Are at ‘The Dawn of a New Era’

Disability Status Linked With Lower Prostate Cancer Screening Rates

Browsing: CD20

Transport of cytotoxic cyanine dyes coupled to siRNA into hematopoietic cancer cells with CD20-, CD22- or CD33-targeting ELART nanocarriers

Flight Attendants and Pilots Have Highest Risk of Dying From Radiation-Linked Cancers, Study Says

New St. Jude CEO Dr. Charles Roberts Says Childhood Cancer Treatments Are at ‘The Dawn of a New Era’

Disability Status Linked With Lower Prostate Cancer Screening Rates

Reversing KDM6A phosphorylation-driven epigenetic suppression restores pyroptosis and synergizes with anti-PD-1 therapy in HNSCC

Flight Attendants and Pilots Have Highest Risk of Dying From Radiation-Linked Cancers, Study Says

New St. Jude CEO Dr. Charles Roberts Says Childhood Cancer Treatments Are at ‘The Dawn of a New Era’

Disability Status Linked With Lower Prostate Cancer Screening Rates

Reversing KDM6A phosphorylation-driven epigenetic suppression restores pyroptosis and synergizes with anti-PD-1 therapy in HNSCC

Latest Post

Flight Attendants and Pilots Have Highest Risk of Dying From Radiation-Linked Cancers, Study Says

New St. Jude CEO Dr. Charles Roberts Says Childhood Cancer Treatments Are at ‘The Dawn of a New Era’

Disability Status Linked With Lower Prostate Cancer Screening Rates

Subscribe to Updates

What's Hot

Browsing: CD20